IBDEI2MF ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,1750,0)
 ;;=CPAP^2^135
 ;;^UTILITY(U,$J,358.4,1751,0)
 ;;=EDUCATION/TRAINING GRP/IND^3^135
 ;;^UTILITY(U,$J,358.4,1752,0)
 ;;=SUPPLIES^10^135
 ;;^UTILITY(U,$J,358.4,1753,0)
 ;;=ESTABLISHED PT-OUTPT^1^136
 ;;^UTILITY(U,$J,358.4,1754,0)
 ;;=INPATIENT CARE^2^136
 ;;^UTILITY(U,$J,358.4,1755,0)
 ;;=COMMON PULMONARY DX^1^137
 ;;^UTILITY(U,$J,358.4,1756,0)
 ;;=SLEEP DISORDERS^20^137
 ;;^UTILITY(U,$J,358.4,1757,0)
 ;;=OBSTRUCTIVE SLEEP APNEA^13^137
 ;;^UTILITY(U,$J,358.4,1758,0)
 ;;=OTHER^26^137
 ;;^UTILITY(U,$J,358.4,1759,0)
 ;;=CANCER^2^137
 ;;^UTILITY(U,$J,358.4,1760,0)
 ;;=CARDIAC^3^137
 ;;^UTILITY(U,$J,358.4,1761,0)
 ;;=ENDOCRINE^4^137
 ;;^UTILITY(U,$J,358.4,1762,0)
 ;;=ENT^5^137
 ;;^UTILITY(U,$J,358.4,1763,0)
 ;;=GASTROINTESTINAL^5^137
 ;;^UTILITY(U,$J,358.4,1764,0)
 ;;=GENITOURINARY/RENAL^6^137
 ;;^UTILITY(U,$J,358.4,1765,0)
 ;;=HEMATOLOGIC/LYMPHATIC^7^137
 ;;^UTILITY(U,$J,358.4,1766,0)
 ;;=HEPATIC/BILIARY^8^137
 ;;^UTILITY(U,$J,358.4,1767,0)
 ;;=INFECTIOUS DISEASE^9^137
 ;;^UTILITY(U,$J,358.4,1768,0)
 ;;=INTERSTITIAL LUNG DISEASE^10^137
 ;;^UTILITY(U,$J,358.4,1769,0)
 ;;=MUSCULOSKELETAL^11^137
 ;;^UTILITY(U,$J,358.4,1770,0)
 ;;=SUTURES^23^137
 ;;^UTILITY(U,$J,358.4,1771,0)
 ;;=RADIATION^19^137
 ;;^UTILITY(U,$J,358.4,1772,0)
 ;;=OCCUPATIONAL^15^137
 ;;^UTILITY(U,$J,358.4,1773,0)
 ;;=PAIN^16^137
 ;;^UTILITY(U,$J,358.4,1774,0)
 ;;=PLEURAL DISEASE^17^137
 ;;^UTILITY(U,$J,358.4,1775,0)
 ;;=PSYCHIATRIC/BEHAVIORAL^18^137
 ;;^UTILITY(U,$J,358.4,1776,0)
 ;;=SKIN^22^137
 ;;^UTILITY(U,$J,358.4,1777,0)
 ;;=NEUROLOGIC^12^137
 ;;^UTILITY(U,$J,358.4,1778,0)
 ;;=OBSTRUCTIVE DISEASE^14^137
 ;;^UTILITY(U,$J,358.4,1779,0)
 ;;=VASCULAR^24^137
 ;;^UTILITY(U,$J,358.4,1780,0)
 ;;=SYMPTOMS^21^137
 ;;^UTILITY(U,$J,358.4,1781,0)
 ;;=ASPIRATION/INJECTION^1^138
 ;;^UTILITY(U,$J,358.4,1782,0)
 ;;=INJECTION MEDICATIONS^2^138
 ;;^UTILITY(U,$J,358.4,1783,0)
 ;;=ULTRASOUND^3^138
 ;;^UTILITY(U,$J,358.4,1784,0)
 ;;=NEW PATIENT^2^139
 ;;^UTILITY(U,$J,358.4,1785,0)
 ;;=ESTABLISHED PATIENT^1^139
 ;;^UTILITY(U,$J,358.4,1786,0)
 ;;=CONSULTATIONS^3^139
 ;;^UTILITY(U,$J,358.4,1787,0)
 ;;=COMMON DIAGNOSES^1^140
 ;;^UTILITY(U,$J,358.4,1788,0)
 ;;=CRYSTAL ARTHROPATHIES^2^140
 ;;^UTILITY(U,$J,358.4,1789,0)
 ;;=JOINT DISORDERS^6^140
 ;;^UTILITY(U,$J,358.4,1790,0)
 ;;=MISCELLANEOUS^7^140
 ;;^UTILITY(U,$J,358.4,1791,0)
 ;;=NERVOUS SYSTEM^8^140
 ;;^UTILITY(U,$J,358.4,1792,0)
 ;;=OSTEOARTHRITIS^9^140
 ;;^UTILITY(U,$J,358.4,1793,0)
 ;;=OSTEOMYELITIS^10^140
 ;;^UTILITY(U,$J,358.4,1794,0)
 ;;=OSTEOPOROSIS^11^140
 ;;^UTILITY(U,$J,358.4,1795,0)
 ;;=PYOGENIC ARTHRITIS^13^140
 ;;^UTILITY(U,$J,358.4,1796,0)
 ;;=SPINE DISORDERS^14^140
 ;;^UTILITY(U,$J,358.4,1797,0)
 ;;=TENDINITIS & BURSITIS^15^140
 ;;^UTILITY(U,$J,358.4,1798,0)
 ;;=VASCULAR DISORDERS^16^140
 ;;^UTILITY(U,$J,358.4,1799,0)
 ;;=VASCULITIS CONDITIONS^17^140
 ;;^UTILITY(U,$J,358.4,1800,0)
 ;;=INFECTIONS^3^140
 ;;^UTILITY(U,$J,358.4,1801,0)
 ;;=INT DERANGEMENT OF KNEE^4^140
 ;;^UTILITY(U,$J,358.4,1802,0)
 ;;=OTHER INFLAMMATORY^12^140
 ;;^UTILITY(U,$J,358.4,1803,0)
 ;;=HISTORY OF^5^140
 ;;^UTILITY(U,$J,358.4,1804,0)
 ;;=RESPIRATORY^9^141
 ;;^UTILITY(U,$J,358.4,1805,0)
 ;;=SLEEP TESTING AND EVAL^10^141
 ;;^UTILITY(U,$J,358.4,1806,0)
 ;;=PULMONARY FUNCTION TESTS^8^141
 ;;^UTILITY(U,$J,358.4,1807,0)
 ;;=ABG/OX/TRANSCUTANEUOUS^1^141
 ;;^UTILITY(U,$J,358.4,1808,0)
 ;;=HOME OXYGEN CLINIC^6^141
 ;;^UTILITY(U,$J,358.4,1809,0)
 ;;=CPAP^2^141
 ;;^UTILITY(U,$J,358.4,1810,0)
 ;;=EDUCATION/TRAINING^3^141
 ;;^UTILITY(U,$J,358.4,1811,0)
 ;;=PROLONGED CLINICAL STAFF SERVICES^7^141
 ;;^UTILITY(U,$J,358.4,1812,0)
 ;;=NEW PATIENT^2^142
